RedHill Biopharma Holds Shareholder Meeting
Ticker: RDHL · Form: 6-K · Filed: Mar 21, 2024 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
Related Tickers: RHBP
TL;DR
RHBP shareholders met March 21st to vote on a key resolution.
AI Summary
RedHill Biopharma Ltd. held an Extraordinary General Meeting of Shareholders on March 21, 2024. The primary purpose of the meeting was to vote on a proposed resolution, the details of which are not fully disclosed in this excerpt, but it was presented for approval.
Why It Matters
Shareholder meetings are crucial for corporate governance, allowing investors to influence company direction and approve significant proposals.
Risk Assessment
Risk Level: low — This filing is a routine report of a shareholder meeting and does not contain new financial or operational risks.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- March 21, 2024 (date) — Date of Extraordinary General Meeting
FAQ
What was the specific resolution presented at the Extraordinary General Meeting?
The provided excerpt states that a 'proposed resolution presented was approve' but does not specify the details of the resolution.
When was the Extraordinary General Meeting of Shareholders held?
The Extraordinary General Meeting of Shareholders of RedHill Biopharma Ltd. was held on March 21, 2024.
What is the principal executive office address for RedHill Biopharma Ltd.?
The principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Does RedHill Biopharma Ltd. file annual reports on Form 20-F or 40-F?
RedHill Biopharma Ltd. files its annual reports on Form 20-F.
What is the Commission File Number for RedHill Biopharma Ltd.?
The Commission File Number for RedHill Biopharma Ltd. is 001-35773.
Filing Stats: 359 words · 1 min read · ~1 pages · Grade level 8.4 · Accepted 2024-03-21 16:05:07
Filing Documents
- zk2431181.htm (6-K) — 11KB
- 0001178913-24-001035.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: March 21, 2024 By: /s/ Dror Ben-Asher Dror Ben-Asher Chief Executive Officer 3